decisionhealth Newsletters, Part B News - 2007 Issue 10 (October)
Epo policy: Groups ask CMS to reconsider decision on ESAs; Groups urge CMS to reconsider Epo policy
Subscribe or sign in to view the full article.
Article Overview
This article covers the Medicare coverage policy change affecting erythropoiesis stimulating agents used in cancer care, the responses from oncology organizations, and the surrounding regulatory and legislative discussion. It is relevant to oncology practices, hematology/oncology billing and compliance staff, and anyone tracking CMS, FDA, and congressional activity affecting supportive care drugs. The article also touches on implementation timing, provider concerns, and the broader disagreement over policy and evidence.
Why This Topic Matters
The policy change has implications for treatment access, office workflow, patient management, and Medicare reimbursement in oncology practices. Readers following coverage policy, compliance, and practice operations will want to understand the issue and the range of responses from CMS, professional societies, manufacturers, and lawmakers.
What You Will Learn
- What CMS changed in its national coverage policy for supportive care drug use in oncology
- How medical societies and other groups responded to the finalized policy
- What CMS said it would consider in revisiting the decision
- How the policy may affect oncology practice operations and patient management
- What congressional and FDA-related actions were discussed in connection with the policy
Who Should Read This
- Oncologists
- Hematologists
- Oncology practice managers
- Medical coders and billers
- Compliance staff
- Health policy professionals
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com